TP53INP1和RAI2在三阴性乳腺癌中的表达及与患者预后的关系

doi:10.3969/j.issn.1671-7171.2023.10.017

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1181 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨三阴性乳腺癌 (TNBC) 组织中TP53INP1、RAI2的表达水平及与患者临床病理特征和预后的关系。【方法】检测168例TNBC患者癌组织及癌旁组织中的TP53INP1和RAI2表达水平,分析其与患者的临床病理特征及预后的关系。【结果】TNBC患者癌组织中的TP53INP1、RAI2的阳性率分别为23.21%(39/168)和 32.74%(55/168),显著低于癌旁组织的53.57%(90/168)和58.93%(99/168)(P<0.05)。TNBC患者的TP53INP1的表达水平与淋巴结转移、病理分期及TMN分期相关(P<0.05),RAI2的表达水平与淋巴结转移、病理分期相关(P<0.05)。单因素分析结果显示,淋巴转移、TNM 分期、TP53INP1 表达及RAI2 表达是影响患者总生存率和无病生存率的危险因素。无淋巴转移、TNM分期Ⅰ~Ⅱ期、TP53INP1高表达、RAI2高表达的5年无病生存率和5年总生存率均显著高于相对应特征患者,且差异具有统计学意义(P<0.05)。Cox风险回归模型分析显示,TP53INP1、RAI2的表达及淋巴转移均是影响患者无病生存期的独立预后因素。【结论】TP53INP1、RAI2的表达水平与TNBC的发生、发展及预后不良密切相关,TP53INP1、RAI2的高表达可能提示预后良好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	逄宗欣
	孙萱
	梁庆娜
	张玲

关键词 ：乳腺肿瘤/病理学, 受体,erbB-2, 雌激素类, 孕酮, 预后

Abstract：【Objective】To investigate the expression levels of TP53INP1 and RAI2 in triple-negative breast cancer (TNBC) tissues and their relationships with the clinical and pathological characteristics and prognosis of patients. 【Methods】The protein expression levels of TP53INP1 and RAI2 in 168 TNBC patients were detected and analyzed in relation to the patients' clinical and pathological characteristics and prognosis. 【Results】The positive rates of TP53INP1 and RAI2 in TNBC cancer tissues were 23.21% (39/168) and 32.74% (55/168) respectively, significantly lower than the 53.57% (90/168) and 58.93% (99/168) in adjacent non-tumor tissues (P<0.05). The expression level of TP53INP1 was correlated with lymph node metastasis, histological grade, and TNM staging (P<0.05), while the expression level of RAI2 was correlated with lymph node metastasis and histological grade (P<0.05). Univariate analysis showed that lymphatic metastasis, TNM stage, TP53INP1 expression, and RAI2 expression were risk factors affecting overall survival and disease-free survival rates. The 5-year disease-free survival rate and overall survival rate of groups without lymph node metastasis, TNM stages Ⅰ-Ⅱ,high TP53INP1 expression, and high RAI2 expression were significantly higher than their corresponding groups, with statistically significant differences (P<0.05). Cox hazard regression model analysis showed that the expressions of TP53INP1, RAI2, and lymph node metastasis were independent prognostic factors affecting disease-free survival. 【Conclusion】The expression levels of TP53INP1 and RAI2 are closely related to the occurrence, progression, and poor prognosis of TNBC. High expression of TP53INP1 and RAI2 may indicate a good prognosis.

Key words： Breast Neoplasms/PA Receptor, ErbB-2 Estrogens Progesterone Prognosis

收稿日期: 2022-12-30

中图分类号:

R737.9

通讯作者: *E-mail:zhangling 565@126.com

引用本文:

逄宗欣, 孙萱, 梁庆娜, 张玲. TP53INP1和RAI2在三阴性乳腺癌中的表达及与患者预后的关系[J]. 医学临床研究, 2023, 40(10): 1500-1503.
PANG Zongxin, SUN Xuan, LIANG Qingna, et al. Expression of TP53INP1 and RAI2 in Triple-Negative Breast Cancer and their Relationship with Patient Prognosis. JOURNAL OF CLINICAL RESEARCH, 2023, 40(10): 1500-1503.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.10.017 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I10/1500

[1] POPEDA M,STOKOWY T,BEDNARZ-KNOLL N,et al.NF-kappa B Signaling-Related signatures are connected with the mesenchymal phenotype of circulating tumor cells in non-metastatic breast cancer[J].Cancers(Basel),2019, 1(12):1961.
[2] WANG Q, GAO J, DI W, et al. Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA overexpressed mouse tumor models[J].Cancer Immunol Immunother,2020, 69(9):1781-1799.
[3] AZIM HA J R,ROTHE F,AURA C M,et al.Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy:A sub-study from the NeoALTTO phase Ⅲ trial[J].Breast,2013,22(6):1060-1065.
[4] 中国女医师协会临床肿瘤学专业委员会. 中国进展期乳腺癌共识指南(CABC 2015)[J].癌症进展, 2015, 13(3):223-245.
[5] LIAO D,LI T,YE C,et al.miR-221 inhibits autophagy and targets TP53INP1 in colorectal cancer cells[J].Exp Ther Med,2018,15(2):1712-1717.
[6] NISHIMOTO M,NISHIKAWA S,KONDO N,et al.Prognostic impact of TP53INP1 gene expression in estrogen receptor α-positive breast cancer patients[J].Jpn J Clin Oncol,2019,49(6):567-575.
[7] FILIPOWICZ W,BHATTACHARYYA SN,SONENBERG N. Mechanisms of post-transcriptional regulation by microRNAs:are the answers in sight[J].Nat Rev Genet,2008,9(2):102-114.
[8] MAYER I A,ABRAMSON V G,FORMISANO L,et al. A Phase Ib study of alpelisib(BYL719) ,a PI3Kα-specific lnhibitor,with letrozole in ER⁺ /HER2-metastatic breast cancer[J].Clin Cancer Res,2017,23(1):26.
[9] SALAZAR LG,LU H,REICHOW JL,et al. Topical imiquimod plus nab-paclitaxel for breast cancer cutaneous metastases:A phase 2 clinical trial[J].JAMA Oncology,2017,3(7):969-973.
[10] GIOVANNELLIP P, DONATO M, AURICCHIO F, et al. Androgens induce invasiveness of triple negative breast cancer cells through AR/Src/PI3-K complex assembly[J].Sci Rep,2019, 9(1):4490.
[11] KIM S B, DENT R, IM S A, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer(LOTUS):a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J].Lancet Oncol,2017, 18(10):1360-1372.
[12] LI C,WANG Q,SHEN S,et al.HIF-1α/VEGF signaling-mediated epithelial - mesenchymal transition and angiogenesis is critically involved in anti - metastasis effect of luteolin in melanoma cells[J].Phytother Res,2019,33(3):798-807.